Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CONCERTA · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CONCERTA (OROS methylphenidate hydrochloride) | DRUG | - |
Inclusion Criteria: * Have a diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) according to the Diagnostic and Statistical Manual of Mental Diseases (DSM-IV) obtained via clinical interview and confirmed by the Wender Utah Rating Scale * ADHD symptoms from childhood to adulthood, with so...
CONCERTA is used for the treatment of Attention Deficit Disorder With Hyperactivity, also known as attention deficit hyperactivity disorder (ADHD). It is a small molecule medication being developed by Johnson & Johnson for this psychiatric condition.
CONCERTA is developed by Johnson & Johnson, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical research on this medication for attention deficit hyperactivity disorder.
CONCERTA is in Phase 3 clinical development. It is an investigational medication for attention deficit hyperactivity disorder and has not been approved by regulatory authorities based on the available clinical trial information.
CONCERTA has one completed clinical trial, identified as NCT00246207. This Phase 3 study evaluated CONCERTA (OROS methylphenidate hydrochloride) for the treatment of attention deficit hyperactivity disorder in adults, enrolling 32 participants aged 18 years and older.
CONCERTA is also known as OROS methylphenidate hydrochloride. The clinical trial NCT00246207 refers to CONCERTA by this alternative name, indicating that both names refer to the same medication being studied for attention deficit hyperactivity disorder.